Advice
Following a resubmission
levetiracetam (Keppra®) is accepted for restricted use within NHS Scotland as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.
Levetiracetam has been shown to be non-inferior to an older first choice anti-epileptic drug for partial seizures.
Levetiracetam is significantly more expensive than traditional drugs so its use is restricted to patients for whom the range of traditional drugs normally used for first-line treatment are ineffective or unsuitable.
Download detailed advice57KB (PDF)
Medicine details
- Medicine name:
- levetiracetam 250 500 750 and 1000mg tablets and levetircetam oral solution 100mg/ml (Keppra)
- SMC ID:
- 397/07
- Indication:
- Monotherapy for epilepsy
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 11 February 2008